AAPGV - Rasio utang marang kapitalisasi buku Ascentage

Tandha merek Ascentage Pharma Group International (AAPGV)

Ascentage Pharma Group (AAPGV) is maneuvering between US and PRC regulators to protect its research. The ratio of total liabilities to book capitalization illustrates the financial leverage dynamics, where the 3.46 metric determines this level. Balance sheet stability is supported by grants from global partners, while the competitive advantage is based on a unique inhibitor platform that blocks tumor cell survival at the molecular level.

AAPGV (Ascentage) riwayat Utang marang nilai buku saka 25.01.2025 nganti 28.10.2026
Barang utama Ascentage

For Ascentage Pharma Group (AAPGV), this indicator determines the stability of financial leverage amid the development of costly drugs. The metric compares total liabilities to the book value of equity, measuring the business's degree of dependence on external financing. By analyzing the capital structure trend—debt to book capitalization—an investor can observe solvency dynamics prior to the release of financial reports. Amid geopolitical tensions between the US and China, low leverage minimizes bankruptcy risks should global drug registration slow down. An optimal debt balance here ensures the company's survival in an environment of limited access to international capital.

Pesaing Ascentage Pharma Group (AAPGV)

Utang-utang marang kapitalisasi buku ONC (BeiGene Ltd)|halozyme.com - Utang-utang marang kapitalisasi buku|Revolution Medicines, Inc. (RVMD) - Rasio utang marang kapitalisasi buku|AAPG - Rasio utang marang nilai buku|CGON (CG Oncology Corp) - Utang-utang marang kapitalisasi buku|UroGen Pharma Corp (URGN) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku BCAX (Bicara Therapeutics Inc.)|Utang-utang marang nilai buku PSNL|Erasca (ERAS) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik Delcath Systems Inc DCTH|Utang marang nilai buku YmAbs|Rasio utang marang aset resik Aura Corp AURA|CADL: Utang-utang marang kapitalisasi buku|accuray.com (ARAY) - Utang marang nilai buku|SLS: Utang marang nilai buku|ACTU (Actuate Therapeutics Inc.) - Utang-utang marang kapitalisasi buku|CTOR - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik TuHURA|Protara Therapeutics - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku fatetherapeutics.com (FATE)|Utang-utang marang kapitalisasi buku WHWK (Aadi Bioscience)|TScan Therapeutics Inc - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku CSBR (Champions Oncology Corp)|XBIT - Utang-utang marang aset resik|CVM (cel-sci.com) - Utang-utang marang kapitalisasi buku|ostherapies.com (OSTX) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku RADX (Radiopharm Theranostics Limited)|Utang-utang marang nilai buku ARTV|Rasio utang marang kapitalisasi buku Adlai Nortye Ltd. ANL|Rasio utang marang nilai buku Veru Corporation VERU|Utang marang nilai buku Tempest Therapeutics (TPST)|Utang marang modal buku Xilio Therapeutics Inc XLO|Enochian BioSciences - Utang-utang marang kapitalisasi buku|MURA - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku KAPA (kairospharma.com)|OnKure Therapeutics (OKUR) - Utang marang aset resik|Utang-utang marang kapitalisasi buku GDTC (CytoMed Therapeutics Ltd)|Utang-utang marang nilai buku Curis Corp (CRIS)|Apollomics, Inc. (APLM) - Utang marang nilai buku|Rasio utang marang aset resik THAR (Tharimmune Inc)|Advanced Biomed (ADVB) - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku Genprex Inc GNPX|Utang-utang marang kapitalisasi buku Calidi Bio (CLDI)|SBFM - Rasio utang marang aset resik|XBIO: Utang-utang marang kapitalisasi buku|SLRX (Salarius Pharmaceuticals Inc) - Utang-utang marang kapitalisasi buku|PPBT - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik AONC|Rasio utang marang kapitalisasi buku BGNE (BeiGene, Ltd.)|Utang marang nilai buku checkpointtx.com (CKPT)|Utang-utang marang kapitalisasi buku ELEV (Elevation Oncology, Inc.)|ICAD - Utang-utang marang kapitalisasi buku|Utang marang nilai buku Ikena (IKNA)|NTBL - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku VIRX (viracta.com)|MOR (morphosys.com) - Utang marang aset resik|NAYA - Rasio utang marang kapitalisasi buku